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BACKGROUND: The possibility of an association of Graves’ disease (GD) with subsequent cancers raised by certain studies.
METHODS: Using a database on 18156 hospitalised GD patients, subsequent cancers were ascertained.
RESULTS: Increased risks of thyroid and parathyroid tumours were limited to the early follow-up period, which is probably a surveillance
bias. Cancer sites with observed excess included the mouth and breast, in contrast to decreased risks of colon cancer, melanoma and
non-Hodgkin’s lymphoma.
CONCLUSION: Increased subsequent cancers in GD patients appeared to be balanced by decreased risks at other sites; chance cannot
be excluded.
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Graves’ disease (GD) is the commonest form of hyperthyroidism,
its annual incidence in Sweden ranging from 20 to 30 per 100000
persons, with an increasing trend in recent years (Abraham-
Nordling et al, 2008; Stalberg et al, 2008) in comparison with
approximately 40 per 100000 in the United States (Stalberg et al,
2008). Graves’ disease is four to six times more common in women
than in men, with a peak incidence between 20 and 60 years (Brent,
2008; Stalberg et al, 2008). It has been suggested that the GD
phenotype reflects an interaction between genetic and environ-
mental factors (Brix et al, 2001; Ringold et al, 2002; Costenbader
and Karlson, 2006). Its treatment includes antithyroid drug
therapy to reduce the level of thyroid hormone, radioactive iodine
I-131 and surgical excision of the thyroid (Brent, 2008; Stalberg
et al, 2008). In Europe, drug therapy is preferred, while radioiodine
and surgery are more often used in the United States (Stalberg
et al, 2008). Therapy-related side effects include inflammation,
agranulocytosis and risk of cancer as response to radioiodine
treatment (Franklyn et al, 1999; Brent, 2008).
The immune system may be involved in cancer development
(de la Cruz-Merino et al, 2008; Prestwich et al, 2008), as possibly in
the dysregulation of the immune system in autoimmune diseases
such as GD. Inconsistent associations between GD and malignant
tumours have been reported (Cristofanilli et al, 2005; Majima et al,
2005; Pazaitou-Panayiotou et al, 2008). Small study size and
variable case reporting weaken the generalisability of the results
(Majima et al, 2005; Pazaitou-Panayiotou et al, 2008). In our
cohort study, the largest to date, 18156 hospitalised GD patients
were studied to quantify their subsequent cancer risk.
MATERIALS AND METHODS
A longitudinal cohort of GD was created by retrieving the details of
patients whose last hospitalised thyroid disease was diagnosed as
GD between 1964 and 2006 in the nationwide Swedish Hospital
Discharge Registry, which is maintained by the National Board of
Health and Welfare. We identified GD patients according to the
seventh (1964–1968 code 252.0), eighth (1969–86 code 242.0),
ninth (1987–96 code 242.0) and tenth (1997–2006 code E05.0)
International Classification of Disease codes. This cohort was
linked to the latest update (end of 2006) of the Swedish Family-
Cancer Database (Hemminki et al, 2008; Ji et al, 2009). Follow-up
for individual risk of malignant tumours was started after the last
hospitalisation for GD, and person-years were calculated until
diagnosis of cancer, death, emigration or closing date of study,
whichever occurred earliest. Considering the concomitant diag-
nosis of GD and relevant malignant tumours, the first follow-up
year was excluded and the risk was reported as All1þ (Hemminki
et al, 2008; Ji et al, 2009). Besides cancers, certain benign tumours,
including parathyroid adenomas, are reported to the cancer
registry (Nilsson et al, 2007; Norenstedt et al, 2009). Carcinomas
and adenomas were distinguished histologically.
Standardised incidence ratios (SIRs) were calculated as the ratio
of observed (O) to expected (E) number of cases. The expected
number was calculated for standard incidence rates adjusted for
age (5-year groups), sex, period (5-year groups), residential area
and socioeconomic status among patients without a history of GD.
The analyses were performed using the SAS statistical package
v 9.1. (SAS Institute Inc., Cary, NC, USA).
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In this cohort of 18156 GD patients, a total of 1495 developed
subsequent cancer during a median follow-up period of 17 years
(0–42 years), giving an overall SIR of 1.13 (95% CI: 1.07–1.19) for
the whole follow-up period as shown in Table 1. Only cancer sites
with at least 20 cases during the whole follow-up period are listed.
The overall SIR among familial cases was 1.66 (n¼32, 95% CI:
1.14–2.35, data not shown), which was mainly contributed by the
increased risk of thyroid gland tumours (n¼8, SIR¼27.21, 95%
CI: 11.62–53.88). To minimise the influence of confounding by
concomitant diagnoses, cancers diagnosed during the first year
after GD were excluded, leaving 1259 cases in the All1þ group;
there was no overall significant excess.
As shown in Table 1, both significantly increased and decreased
cancer risks after GD were noted. The SIRs were very high for
thyroid and other endocrine gland tumours within 1 year of the
last hospitalisation for GD; after excluding these cases the risks
were not significant. Among 164 thyroid cancers, 89 were
categorised as papillary adenocarcinoma, which accounted for
84% of the histologically defined cases available since 1993
(SIR¼19.27, 95% CI: 15.47–23.72); among all thyroid cancers in
the database, papillary histology accounted for 62%. Other
endocrine tumours were histologically dominated by parathyroid
adenomas (87%) with an increased risk of 2.55 (n¼62, 95% CI:
1.96–3.27). The risks of upper aerodigestive tract and breast
cancers were significantly increased in both All and All1þ, the
risk for mouth cancer being significantly increased (SIR¼2.30,
n¼9, 95% CI: 1.04–4.38). Significantly decreased risks were
observed for colon cancer, melanoma and non-Hodgkin’s
lymphoma.
In subsequent cancer assay the cohort of 1259 patients in the
All1þ category was dominated by women (n¼1018, male¼241,
data not shown), who showed a significantly increased risk of
breast cancer, whereas the risks for colon cancer and non-
Hodgkin’s lymphoma were decreased. Only male patients showed
an increased risk of thyroid cancer (SIR¼5.14).
As a possible predictor of disease severity, we examined cancer
risks after GD by the number of hospitalisations. Multiple
hospitalisations were associated with an increased risk of breast
cancer (SIR¼1.29 for X2 hospitalisations vs 1.06 for 1
hospitalisation). Late age at last hospitalisation (X40 years) was
significantly associated with higher risks of lung (SIR¼1.36, 95%
CI: 1.06–1.71), breast (SIR¼1.24, 95% CI: 1.10–1.40) and thyroid
(SIR¼1.89, 95% CI: 1.00–3.24) cancers (data not shown).
DISCUSSION
The present study is the largest to date and has the longest follow-up.
The overall excess of all cancers (13%) was largely attributable to
cancers of the thyroid, other endocrine glands, upper aerodigestive
tract and breast. Risks for colon cancer, melanoma and non-
Hodgkin’s lymphoma were significantly decreased. Studies have
shown that all patients with hyperthyroidism or GD in Sweden are
hospitalised (Abraham-Nordling et al, 2008; Lantz et al, 2009). A
national coverage with medically diagnosed GD cases in specialist
settings provided reliable diagnostic data; limitations include the
lack of data on smoking, medication and treatment. Moreover,
some associations could be chance findings due to multiple
comparisons.
An overall excess of subsequent cancers after GD was limited to
the first year of follow-up and no risk was observed in the All1þ
category, contrasting with certain reports (Munoz et al, 1978;
Hancock et al, 1995; Franklyn et al, 1999). The high overall risk of
6.96 within the first year of hospitalisation may reflect medical
surveillance (Hemminki et al, 2008; Ji et al, 2009). However, for
subsequent periods (All1þ), the true risk might be under-
estimated, because the accuracy of diagnosis of cancers was not
compromised by lead-time bias: the diagnosis was just shifted to
an earlier time.
For thyroid cancer, previous studies have reported inconsistent
results (Cole, 1991; Majima et al, 2005; Pazaitou-Panayiotou et al,
2008). We found increased risks, confined to the early overall
Table 1 SIRs for subsequent cancers in patients hospitalised for Graves’ disease by follow-up time
Follow-up interval (years)
o11 – 4 5 – 9 X10 All All 1+
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 2 3.60 0.34 13.23 4 1.64 0.43 4.23 6 1.76 0.63 3.85 21 1.43 0.88 2.19 33 1.56 1.08 2.20 31 1.51 1.02 2.14
Stomach 2 3.43 0.32 12.62 0 7 1.76 0.70 3.64 15 0.73 0.41 1.20 24 0.86 0.55 1.28 22 0.81 0.51 1.22
Colon 0 8 0.78 0.33 1.55 11 0.75 0.37 1.34 59 0.81 0.61 1.04 78 0.78 0.61 0.97 78 0.80 0.63 0.99
Rectum 1 0.87 0.00 4.98 6 1.16 0.42 2.55 5 0.66 0.21 1.56 28 0.75 0.50 1.09 40 0.78 0.56 1.07 39 0.78 0.56 1.07
Liver 0 2 0.94 0.09 3.45 3 0.88 0.17 2.59 23 1.10 0.70 1.66 28 1.04 0.69 1.51 28 1.06 0.70 1.53
Pancreas 1 2.45 0.00 14.02 2 1.02 0.10 3.76 1 0.31 0.00 1.80 21 1.04 0.64 1.60 25 0.97 0.63 1.44 24 0.95 0.61 1.41
Lung 2 1.57 0.15 5.77 13 2.14 1.13 3.66 13 1.34 0.71 2.29 60 1.05 0.80 1.35 88 1.19 0.95 1.46 86 1.18 0.94 1.46
Breast 15 1.61 0.90 2.67 49 1.19 0.88 1.57 69 1.20 0.94 1.52 259 1.09 0.96 1.24 392 1.14 1.03 1.26 377 1.12 1.01 1.24
Cervix 1 0.70 0.00 4.01 3 0.53 0.10 1.57 9 1.39 0.63 2.65 13 0.81 0.43 1.39 26 0.88 0.57 1.29 25 0.89 0.57 1.31
Endometrium 2 1.01 0.10 3.73 7 0.82 0.33 1.70 21 1.83 1.13 2.79 41 0.81 0.58 1.09 71 0.97 0.76 1.23 69 0.97 0.76 1.23
Ovary 1 0.73 0.00 4.17 3 0.50 0.10 1.49 6 0.75 0.27 1.64 32 0.96 0.66 1.36 42 0.86 0.62 1.17 41 0.87 0.62 1.18
Prostate 2 1.18 0.11 4.33 7 0.88 0.35 1.83 10 0.79 0.38 1.46 63 0.95 0.73 1.21 82 0.92 0.73 1.15 80 0.92 0.73 1.14
Kidney 2 2.89 0.27 10.61 6 1.95 0.70 4.27 5 1.15 0.36 2.69 21 1.02 0.63 1.56 34 1.18 0.82 1.66 32 1.14 0.78 1.61
Urinary bladder 2 1.76 0.17 6.49 11 2.19 1.09 3.93 8 1.11 0.48 2.20 37 1.12 0.79 1.55 58 1.25 0.95 1.62 56 1.24 0.94 1.61
Melanoma 4 2.13 0.55 5.50 4 0.50 0.13 1.29 14 1.34 0.73 2.25 19 0.53 0.32 0.82 41 0.73 0.52 0.99 37 0.68 0.48 0.94
Skin 0 4 0.71 0.18 1.83 11 1.32 0.66 2.37 29 0.70 0.47 1.01 44 0.78 0.57 1.05 44 0.80 0.58 1.07
Nervous system 8 6.57 2.81 13.01 6 1.14 0.41 2.50 4 0.57 0.15 1.48 24 0.90 0.58 1.35 42 1.05 0.76 1.42 34 0.88 0.61 1.23
Thyroid gland 145 234.07 197.52 275.47 10 4.04 1.93 7.46 2 0.70 0.07 2.58 7 0.92 0.36 1.90 164 12.08 10.30 14.07 19 1.47 0.88 2.29
Endocrine glands 44 42.17 30.63 56.64 7 1.57 0.62 3.25 8 1.37 0.58 2.71 12 0.57 0.29 1.00 71 2.20 1.71 2.77 27 0.86 0.57 1.26
Parathyroid 42 50.80 36.60 68.71 5 1.45 0.46 3.42 5 1.14 0.36 2.68 10 0.65 0.31 1.20 62 2.55 1.96 3.27 20 0.86 0.53 1.33
Non-Hodgkin’s lymphoma 1 1.09 0.00 6.25 2 0.48 0.05 1.78 5 0.83 0.26 1.95 18 0.62 0.36 0.98 26 0.64 0.42 0.95 25 0.63 0.41 0.94
Leukaemia 0 1 0.31 0.00 1.76 4 0.84 0.22 2.18 22 0.96 0.60 1.45 27 0.85 0.56 1.24 27 0.87 0.57 1.27
All 236 6.96 6.10 7.91 162 1.08 0.92 1.26 233 1.11 0.97 1.26 864 0.93 0.87 0.99 1495 1.13 1.07 1.19 1259 0.97 0.92 1.03
Abbreviations: O¼observed; SIR¼standardised incidence ratio; CI¼confidence interval. Bold type, 95% CI does not include 1.00; bold type with underline, 99% CI does not
include 1.00.
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yfollow-up period, though for men the risk was noted even for the
All1þ period. The prevalence of occult thyroid tumours has been
reported to be about 13% in an autopsy examination; these may
remain clinically silent for a lifetime (Angusti et al, 2000). The
commonest type, papillary adenocarcinoma, is most closely linked
to radiation (Delellis et al, 2004). Our finding of an increased risk
of parathyroid adenoma after GD could be related to surveillance
bias or radioiodine treatment, as with thyroid cancer.
An association of breast cancer with thyroid disease is a long-
debated issue (Ito and Maruchi, 1975; Smyth et al, 1998). Our
results on an increased risk of breast cancer, especially for women
with multiple hospitalisations, raise the possibility that thyroid
hormones play a role in the aetiology of breast carcinoma
(Cristofanilli et al, 2005). As smoking is a common risk factor
for GD and cancers of the lung, upper aerodigestive tract and
urinary bladder (Nomura, 1982; Costenbader and Karlson, 2006),
the excesses of these cancers could be due to smoking. Among
upper aerodigestive tract cancers, mouth cancer risk was increased
2.3 times, in line with an American cohort study, probably
indicating treatment effects (Goldman et al, 1990).
The deficiencies, particularly among women, of colon cancer,
melanoma and non-Hodgkin’s lymphoma are novel to our
knowledge. These could be caused either by autoimmunity of
GD, especially for melanoma and non-Hodgkin’s lymphoma, or by
pathological thyroid hormone excess (de la Cruz-Merino et al,
2008; Prestwich et al, 2008). Thyroid-stimulating hormone is a
growth factor for melanoma cells, and so low levels of this
hormone in GD may suppress melanoma development (Ellerhorst
et al, 2006).
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